Literature DB >> 28449488

Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation.

Hui Ning1,2, Ming Liu1, Lina Wang3, Yang Yang1, Nan Song1, Xiaoxiong Xu1, Jin Ju4, Gening Jiang1.   

Abstract

BACKGROUND: Epidermal growth factor receptor (EGFR) gene was the major causative gene of lung cancer and also the specific treatment target. It is necessary to analyze the genotype and phenotype characters of patients.
METHODS: We investigated 1,034 lung cancer patients in this study. The collected clinicopathological parameters included gender, age at diagnosis, smoking status, pathological TNM stage, tumor morphology and location, visceral pleural invasion as well as histological type.
RESULTS: Almost 50% participants had EGFR mutations. L858R in exon 21 was the most common type. Concomitant mutation, 19 del and L858R, were detected in 20 patients. Compared to patients with exon 19 del or L858R mutations solely, they were inclined to have small size adenocarcinomas which occurred in bilateral and invaded the visceral pleura. The tyrosine kinases inhibitors (TKIs)-resistant mutation, insertions in exon 20, was detected in 11 patients.
CONCLUSIONS: The summarized clinicopathological features will help clinicians to implement the feasible treatment plan.

Entities:  

Keywords:  Lung cancer; epidermal growth factor receptor (EGFR) gene; genotype; mutation; phenotype

Year:  2017        PMID: 28449488      PMCID: PMC5394029          DOI: 10.21037/jtd.2017.03.13

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  25 in total

Review 1.  Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.

Authors:  S K Chan; W J Gullick; M E Hill
Journal:  Eur J Cancer       Date:  2006-01       Impact factor: 9.162

Review 2.  EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

Authors:  Hiroyuki Yasuda; Susumu Kobayashi; Daniel B Costa
Journal:  Lancet Oncol       Date:  2011-07-19       Impact factor: 41.316

3.  Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase.

Authors:  Ibrahim F Benter; Mariam H M Yousif; Andrew J Hollins; Sioned M Griffiths; Saghir Akhtar
Journal:  J Vasc Res       Date:  2005-05-23       Impact factor: 1.934

4.  Frequency of and variables associated with the EGFR mutation and its subtypes.

Authors:  Tomoaki Tanaka; Masaru Matsuoka; Akihisa Sutani; Akihiko Gemma; Makoto Maemondo; Akira Inoue; Shoji Okinaga; Makoto Nagashima; Satoshi Oizumi; Kazutsugu Uematsu; Yoshiaki Nagai; Gaku Moriyama; Hitoshi Miyazawa; Kenji Ikebuchi; Satoshi Morita; Kunihiko Kobayashi; Koichi Hagiwara
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

5.  Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.

Authors:  Tony K F Yung; K C Allen Chan; Tony S K Mok; Joanna Tong; Ka-Fai To; Y M Dennis Lo
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

6.  Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population.

Authors:  Edmund S Kassis; Ara A Vaporciyan; Stephen G Swisher; Arlene M Correa; B Nebiyou Bekele; Jeremy J Erasmus; Wayne L Hofstetter; Ritsuko Komaki; Reza J Mehran; Cesar A Moran; Katherine M Pisters; David C Rice; Garrett L Walsh; Jack A Roth
Journal:  J Thorac Cardiovasc Surg       Date:  2009-05-28       Impact factor: 5.209

7.  Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.

Authors:  Aristea Kalikaki; Anastasios Koutsopoulos; Dora Hatzidaki; Maria Trypaki; Emmanouel Kontopodis; Efstathios Stathopoulos; Dimitris Mavroudis; Vassilis Georgoulias; Alexandra Voutsina
Journal:  Lung Cancer       Date:  2009-10-24       Impact factor: 5.705

8.  Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma.

Authors:  Wei Ping; Chunjiao Xia; Shengling Fu; Yixin Cai; Yu Deng; Wei Sun; Cuiping Dong; Xiangning Fu
Journal:  Tumour Biol       Date:  2014-10-07

9.  EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study.

Authors:  Sema Bircan; Huseyin Baloglu; Zafer Kucukodaci; Ahmet Bircan
Journal:  Med Oncol       Date:  2014-06-29       Impact factor: 3.064

10.  Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes.

Authors:  Xiangli Jiang; Bo Yang; Jiuqin Lu; Zhongli Zhan; Kai Li; Xiubao Ren
Journal:  Tumour Biol       Date:  2014-10-10
View more
  2 in total

1.  Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma.

Authors:  Ming Li; Chuanying Li; Li Ke; Mali Zhan; Min Cheng
Journal:  Oncol Lett       Date:  2018-10-02       Impact factor: 2.967

2.  Development and Validation of a Concise Prediction Scoring System for Asian Lung Cancer Patients with EGFR Mutation Before Treatment.

Authors:  Wenting An; Wei Fan; Feiyang Zhong; Binchen Wang; Shan Wang; Tian Gan; Sufang Tian; Meiyan Liao
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.